Patents by Inventor Marie-Christine Wolf

Marie-Christine Wolf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Therapeutic regimen
    Patent number: 11738028
    Abstract: The present invention relates to dosing regimen of a new antimalarial drug, as monotherapy or combination therapy.
    Type: Grant
    Filed: July 29, 2021
    Date of Patent: August 29, 2023
    Assignee: Novartis AG
    Inventors: Jay Prakash Jain, Franz Joel Leong, Cornelis Winnips, Marie-Christine Wolf
  • THERAPEUTIC REGIMEN
    Publication number: 20220088022
    Abstract: The present invention relates to dosing regimen of a new antimalarial drug, as monotherapy or combination therapy.
    Type: Application
    Filed: July 29, 2021
    Publication date: March 24, 2022
    Inventors: Jay Prakash JAIN, Franz Joel LEONG, Cornelis WINNIPS, Marie-Christine WOLF
  • Preparation of and formulation comprising a MEK inhibitor
    Patent number: 10729678
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Grant
    Filed: July 16, 2019
    Date of Patent: August 4, 2020
    Assignee: Array BioPharma Inc.
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • PREPARATION OF AND FORMULATION COMPRISING A MEK INHIBITOR
    Publication number: 20200171002
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Application
    Filed: July 16, 2019
    Publication date: June 4, 2020
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • THERAPEUTIC REGIMEN
    Publication number: 20200171037
    Abstract: The present invention relates to dosing regimen of a new antimalarial drug, as monotherapy or combination therapy.
    Type: Application
    Filed: October 30, 2019
    Publication date: June 4, 2020
    Inventors: Jay Prakash JAIN, Franz Joel LEONG, Cornelis WINNIPS, Marie-Christine WOLF
  • Preparation of and formulation comprising a MEK inhibitor
    Patent number: 10398683
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Grant
    Filed: December 14, 2017
    Date of Patent: September 3, 2019
    Assignee: Array BioPharma Inc.
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • THERAPEUTIC REGIMEN
    Publication number: 20180303837
    Abstract: The present invention relates to dosing regimen of a new antimalarial drug, as monotherapy or combination therapy.
    Type: Application
    Filed: April 24, 2018
    Publication date: October 25, 2018
    Inventors: Jay Prakash JAIN, Franz Joel LEONG, Cornelis WINNIPS, Marie-Christine WOLF
  • PREPARATION OF AND FORMULATION COMPRISING A MEK INHIBITOR
    Publication number: 20180296533
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Application
    Filed: December 14, 2017
    Publication date: October 18, 2018
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • Preparation of and formulation comprising a MEK inhibitor
    Patent number: 9980944
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Grant
    Filed: February 28, 2017
    Date of Patent: May 29, 2018
    Assignee: Array BioPharma Inc.
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • PREPARATION OF AND FORMULATION COMPRISING A MEK INHIBITOR
    Publication number: 20170231963
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Application
    Filed: February 28, 2017
    Publication date: August 17, 2017
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • Preparation of and formulation comprising a MEK inhibitor
    Patent number: 9598376
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro -3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Grant
    Filed: February 25, 2016
    Date of Patent: March 21, 2017
    Assignees: Array BioPharma, Inc., Novartis AG
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • Preparation of and formulation comprising a MEK inhibitor
    Patent number: 9562016
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: February 7, 2017
    Assignees: Array BioPharma, Inc., Novartis AG
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • Preparation of and formulation comprising a MEK inhibitor
    Patent number: 9382212
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Grant
    Filed: December 18, 2015
    Date of Patent: July 5, 2016
    Assignees: Array BioPharma, Inc., Novartis AG
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • PREPARATION OF AND FORMULATION COMPRISING A MEK INHIBITOR
    Publication number: 20160168104
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro -3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Application
    Filed: February 25, 2016
    Publication date: June 16, 2016
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • PREPARATION OF AND FORMULATION COMPRISING A MEK INHIBITOR
    Publication number: 20160168102
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Application
    Filed: December 18, 2015
    Publication date: June 16, 2016
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • PREPARATION OF AND FORMULATION COMPRISING A MEK INHIBITOR
    Publication number: 20160168103
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Application
    Filed: December 18, 2015
    Publication date: June 16, 2016
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • Preparation of and formulation comprising a MEK inhibitor
    Patent number: 9238627
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Grant
    Filed: October 18, 2013
    Date of Patent: January 19, 2016
    Assignees: Array BioPharma, Inc., Novartis AG
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • PREPARATION OF AND FORMULATION COMPRISING A MEK INHIBITOR
    Publication number: 20140128442
    Abstract: The present invention relates to processes for preparing 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, processes for preparing crystallized 6-(4-bromo-2-fluorophenylamino)-7-fluoro-3-methyl-3H-benzoimidazole-5-carboxylic acid (2-hydroxyethyoxy)-amide, and intermediates useful therefore. Also provided herein are pharmaceutical compositions comprising this crystallized compound.
    Type: Application
    Filed: October 18, 2013
    Publication date: May 8, 2014
    Applicants: Array BioPharma, Inc., Novartis AG
    Inventors: Christoph Max Krell, Marian Misun, Daniel Andreas Niederer, Werner Heinz Pachinger, Marie-Christine Wolf, Daniel Zimmermann, Weidong Liu, Peter J. Stengel, Paul Nichols
  • GALENICAL FORMULATIONS OF ORGANIC COMPOUNDS
    Publication number: 20100209480
    Abstract: The present invention relates to a pharmaceutical oral fixed dose combination comprising a) a therapeutically effective amount of Aliskiren, or a pharmaceutically acceptable salt thereof, b) a therapeutically effective amount of Valsartan, or a pharmaceutically acceptable salt thereof, wherein the pharmaceutical oral fixed dose combination shows an in vitro dissolution of component a) of 80% or less after 10 minutes and 98% or less after 20 minutes, and a dissolution profile of component b) of 25% or more after 30 minutes, and 40% or more after 60 minutes at pH 4.5.
    Type: Application
    Filed: September 24, 2008
    Publication date: August 19, 2010
    Inventors: Ralf Altenburger, Maggy B. Saunier, Nicole Bargenda, Michael A. Bock, Sabine Adler, Bruno Buss, Catherine Curdy, Indrajit Ghosh, Stefan Hirsch, Patrice F. Keller, Charu Kochhar, Shoufeng Li, Nicoletta Loggia, Amol S. Matharu, Julien Taillemite, Wei-Qin Tong, Sudha Vippagunta, Hong Wen, Marie-Christine Wolf, Jay P. Lakshman, James Kowalski
  • Pharmaceutical Composition Comprising an Indolylmaleimide Derivative
    Publication number: 20080187582
    Abstract: The application relates to solid pharmaceutical compositions suitable for oral administration comprising a water sensitive drug, preferably an indolylmaleimide derivative, process for their production and use of the pharmaceutical compositions.
    Type: Application
    Filed: February 27, 2006
    Publication date: August 7, 2008
    Inventors: Patrice Guitard, Marie-Christine Wolf